Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefazolin + tinidazole
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
A combination antibiotic therapy consisting of cefazolin, a broad-spectrum cephalosporin antibiotic, and tinidazole, a nitroimidazole antiprotozoal agent. Cefazolin works by inhibiting bacterial cell wall synthesis and is primarily used for treating skin infections and other moderate to severe bacterial infections in various body sites. Tinidazole is effective against protozoan parasites and certain anaerobic bacteria. This combination may provide coverage against both aerobic bacteria and anaerobic microorganisms.
02
Targets
NeuraminidasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on cefazolin + tinidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefazolin + tinidazole.